Photo - Vulcan Biologics
61099

Vulcan Biologics

USA, California
Market: Biotech
Stage of the project: Prototype or product is ready

Date of last change: 28.11.2023
Go to the owner's profile
4
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

MIT/Harvard synthetic biology startup, innovating in-situ human therapeutics with minimal side effects. Focusing on IBD, autoimmune diseases, and cancers like CRC, PDAC.

Current Status

In vitro, co-culture with mammalian reporter cells.

Problem or Opportunity

Including but not limited to gastrointestinal disorders such as IBD, autoimmune diseases, or even in oncology (CRC, PDAC, etc.).

Solution (product or service)

Vulcan intends to use synthetic biology to engineer bacteria in situ, embedding new functionality into existing and engrafted microbes to deliver therapeutic effects. This is achieved by leveraging engineered, integrative bacteriophages to modify specific bacterial populations long-term, similar to gene therapy.

Business model

Tx dev and Licensing
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility183
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Product Video
Presentation